JUN 19, 2017 11:32 AM PDT

FDA Wants Opioid Opana Off the Market

WRITTEN BY: Xuan Pham

In a first, the US FDA requested that Opana ER (oxymorphone hydrochloride), an opioid painkiller, be voluntarily removed from the market. The FDA based this decision on the drug’s capacity for abuse, and that its mode of administration (injection) has been linked to transmission of diseases like HIV and hepatitis C.

Image credit: Pixabay.com

“We are facing an opioid epidemic – a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse,” said Scott Gottlieb, FDA Commissioner. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse.”

The opioid is manufactured by Endo Pharmaceuticals, and was approved over a decade ago for the treatment of moderate or severe chronic pain. The potent extended-release formula proved effective at relieving pain, but also quite dangerous for misuse. Following these criticisms, Endo reformulated the drug in 2012, supposedly making the drug more difficult to abuse.

However, the FDA determined that the reformulation did not “meaningfully reduce abuse.” Specifically, it seems that the drug is now being abused by injection rather than snorting. And this mode of abuse has been linked to outbreaks of HIV and hepatitis C via contaminated needles. In addition, abuse of Opana ER has been linked to another serious blood disorder, known as thrombotic microangiopathy.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak," said Dr. Janet Woodcock, the director of the FDA's Center for Drug Evaluation and Research, in a statement.

"When we determined that the product had dangerous and unintended consequences, we made a decision to request its withdrawal from the market," said Woodcock. "This action will protect the public from further potential for misuse and abuse of this product.”

The FDA’s polite request may make it appear as though Endo Pharmaceuticals could have a say in whether or not to comply. In actuality, if the company does not voluntarily pull its product off the shelf, the FDA will more than likely revoke their approval and force the drug off the shelf.

Endo responded to the request, saying that the company is “reviewing the request and is evaluating the full range of potential options as we determine the appropriate path forward." Furthermore, the company defended their drug’s efficacy at relieving pain. "As a pharmaceutical company with a demonstrated commitment to the improvement of pain management, Endo feels a strong sense of responsibility to improve the care of pain for patients, while at the same time taking comprehensive steps to minimize the potential misuse of its products.”

Additional source: Live Science

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 13, 2019
Clinical & Molecular DX
SEP 13, 2019
Apple Watch New Research App: A Boon to Women's Health
The Apple company, in 2018, enrolled more than 400,000 people in its Apple Heart Study conducted in partnership with Stanford University researchers....
NOV 14, 2019
Chemistry & Physics
NOV 14, 2019
Examining the Squirrelly Ones: Wearable MEG Scanner that Suits Pediatric Patients
In a recent study, a joint research team at the University of Nottingham, University of Oxford, and University College London successfully tested a ne...
DEC 04, 2019
Clinical & Molecular DX
DEC 04, 2019
Genetic platform takes the guesswork out of catching infections
A physician is faced with 3 patients: an elderly person with a chronic cough, a child being wheeled out of surgery and a young mother with a high fever. Ho...
DEC 11, 2019
Health & Medicine
DEC 11, 2019
Can optical illusions help diagnose autism?
At first glance what do you see -- a young woman? Or perhaps a smooth jazz artist? This classic optical illusion occurs due to a phenomenon known as binocu...
FEB 10, 2020
Microbiology
FEB 10, 2020
As Ebola Outbreak Continues, Researchers Create Faster Genetic Test
Since 2013, around 30,000 people have been infected during several outbreaks of Ebola in eight different countries....
MAR 29, 2020
Cancer
MAR 29, 2020
MicroRNA as a New Way to Test for Lung Cancer
The most common, and most deadly, cancer across the world is lung cancer. If caught early, lung cancer has quite a low mortality rate. MicroRNAs may prove to be the answer....
Loading Comments...